Hyperplasia

Pulse Biosciences Announces FDA IDE Approval and Initiation of Sebaceous Hyperplasia Study

Retrieved on: 
Thursday, October 1, 2020
Medical devices, FDA, Health, Other Health, Pharmaceutical, Biotechnology, Human sexuality, Branches of biology, Biology, Investigational device exemption, Pharmaceutical industry, IDE, Food and Drug Administration, Sebaceous gland, Erotic electrostimulation, Hyperplasia, Insulin-degrading enzyme, Sebaceous Hyperplasia, Pulse Biosciences®

Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation (NPS) technology, today announced FDA Investigational Device Exemption (IDE) approval and initiation of a pivotal study to evaluate the treatment of sebaceous hyperplasia (SH) lesions using the CellFX System.

Key Points: 
  • Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation (NPS) technology, today announced FDA Investigational Device Exemption (IDE) approval and initiation of a pivotal study to evaluate the treatment of sebaceous hyperplasia (SH) lesions using the CellFX System.
  • Following IDE approval, several patients have been enrolled, with the first patient procedure completed on September 28, 2020.
  • We are pleased to have received FDA IDE approval and to have begun this important SH comparative study slightly ahead of the fourth quarter start we had previously communicated.
  • Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.

US Benign Prostatic Hyperplasia Market 2020: Pipeline Products, Epidemiology, Drug Sales, Market Valuations and Forecasts

Retrieved on: 
Tuesday, September 22, 2020
Medicine, RTT, Health, Medical specialties, Andrology, Benign prostatic hyperplasia, Men's Health, Hyperplasia, 5α-Reductase inhibitors, Benignity, Cioteronel, TUMT

The latest research provides comprehensive insights into Benign Prostatic Hyperplasia pipeline products, Benign Prostatic Hyperplasia epidemiology, Benign Prostatic Hyperplasia market valuations and forecast, Benign Prostatic Hyperplasia drugs sales and competitive landscape in the US.

Key Points: 
  • The latest research provides comprehensive insights into Benign Prostatic Hyperplasia pipeline products, Benign Prostatic Hyperplasia epidemiology, Benign Prostatic Hyperplasia market valuations and forecast, Benign Prostatic Hyperplasia drugs sales and competitive landscape in the US.
  • The research is classified into seven sections - Benign Prostatic Hyperplasia treatment options, pipeline products, market analysis comprising of epidemiology, key products marketed, market valuations and forecast, drugs sales and market shares.
  • Benign Prostatic Hyperplasia pipeline: Find out the products in clinical trials for the treatment of Benign Prostatic Hyperplasia by development phase 3, phase 2, and phase 1, by pharmacological class and companies developing the products
    Benign Prostatic Hyperplasia drugs: Identify key products marketed and prescribed for Benign Prostatic Hyperplasia in the US, including trade name, molecule name, and company
    Benign Prostatic Hyperplasia drugs sales: Find out the sales revenues of Benign Prostatic Hyperplasia drugs in the US
    Benign Prostatic Hyperplasia market valuations: Find out the market size for Benign Prostatic Hyperplasia drugs in 2019 in the US.
  • Find out how the market advanced from 2016 and forecast to 2025
    Benign Prostatic Hyperplasia drugs market share: Find out the market shares for key Benign Prostatic Hyperplasia drugs in the US
    Evaluate commercial market opportunity assessment, positioning, and segmentation for Benign Prostatic Hyperplasia products
    1.

United States Benign Prostatic Hyperplasia Market and Competitive Landscape 2020 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, September 16, 2020
Pharmaceutical, Health, Clinical trials, RTT, Medicine, Medical specialties, Andrology, Health, Benign prostatic hyperplasia, Men's Health, Benignity, Hyperplasia

The "US Benign Prostatic Hyperplasia Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "US Benign Prostatic Hyperplasia Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.
  • The latest research provides comprehensive insights into Benign Prostatic Hyperplasia pipeline products, Benign Prostatic Hyperplasia epidemiology, Benign Prostatic Hyperplasia market valuations and forecast, Benign Prostatic Hyperplasia drugs sales and competitive landscape in the US.
  • Benign Prostatic Hyperplasia pipeline: Find out the products in clinical trials for the treatment of Benign Prostatic Hyperplasia by development phase 3, phase 2, and phase 1, by pharmacological class and companies developing the products
    Benign Prostatic Hyperplasia drugs: Identify key products marketed and prescribed for Benign Prostatic Hyperplasia in the US, including trade name, molecule name, and company
    Benign Prostatic Hyperplasia drugs sales: Find out the sales revenues of Benign Prostatic Hyperplasia drugs in the US
    Benign Prostatic Hyperplasia market valuations: Find out the market size for Benign Prostatic Hyperplasia drugs in 2019 in the US.
  • Find out how the market advanced from 2016 and forecast to 2025
    Benign Prostatic Hyperplasia drugs market share: Find out the market shares for key Benign Prostatic Hyperplasia drugs in the US
    Evaluate commercial market opportunity assessment, positioning, and segmentation for Benign Prostatic Hyperplasia products
    1.

Spruce Biosciences Announces Key Management and Board Appointments

Retrieved on: 
Wednesday, September 9, 2020
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical trials, Adrenal gland disorders, Anatomy, Medical specialties, Organ systems, Congenital adrenal hyperplasia, Hyperplasia, CAH, Endocrine disease, Adrenal gland, Endocrine system

The appointments coincide with progress into Phase 2b clinical trials of tildacerfont in adult classic congenital adrenal hyperplasia (CAH).

Key Points: 
  • The appointments coincide with progress into Phase 2b clinical trials of tildacerfont in adult classic congenital adrenal hyperplasia (CAH).
  • Dr. Dias joins Spruce most recently from Indivior, where he was the Chief Medical Officer for the past year.
  • I am delighted to join the members of Spruces board and management team to help bring important new treatment options to patients in need.
  • Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet need.

Crinetics Pharmaceuticals Provides New Data from Paltusotine and ACTH Antagonist Development Programs at European Congress of Endocrinology

Retrieved on: 
Friday, September 4, 2020
Endocrine diseases, Adrenal gland disorders, Organ systems, Endocrinology, RTT, Cushing's syndrome, Adrenocorticotropic hormone, Congenital adrenal hyperplasia, Acromegaly, Adrenal gland, Hyperplasia, Late onset congenital adrenal hyperplasia

Crinetics is developing an ACTH antagonist for the treatment of diseases associated with excess ACTH such as Cushings disease and congenital adrenal hyperplasia (CAH).

Key Points: 
  • Crinetics is developing an ACTH antagonist for the treatment of diseases associated with excess ACTH such as Cushings disease and congenital adrenal hyperplasia (CAH).
  • We look forward to achieving the next milestone in this program by advancing our lead ACTH antagonist candidate into Phase 1.
  • Adverse events associated with paltusotine were generally mild and transient and were consistent with those reported withother somatostatin agonists.
  • The results of this study suggest that paltusotine exhibits excellent properties appropriate for chronic once-daily oral treatment of patients with acromegaly.

2020 Worldwide Benign Prostatic Hyperplasia Clinical Trial Pipeline Highlights - ResearchAndMarkets.com

Retrieved on: 
Friday, July 17, 2020
General Health, Pharmaceutical, Health, Clinical trials, Medicine, Health, Medical specialties, RTT, Andrology, Benign prostatic hyperplasia, Men's Health, Hyperplasia, Anti-acne preparations, Clinical trial, Benignity, Cioteronel

The "Global Benign Prostatic Hyperplasia Clinical Trial Pipeline Highlights - 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Benign Prostatic Hyperplasia Clinical Trial Pipeline Highlights - 2020" report has been added to ResearchAndMarkets.com's offering.
  • This report provides the most up-to-date information on key pipeline products in the global Benign Prostatic Hyperplasia market.
  • It covers emerging therapies for Benign Prostatic Hyperplasia in active clinical development stages including early and late-stage clinical trials.
  • The report provides Benign Prostatic Hyperplasia pipeline products by clinical trial stages including both early and late-stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Insights into the Global Benign Prostatic Hyperplasia Market to 2024 - Evaluate Commercial Market Opportunities - ResearchAndMarkets.com

Retrieved on: 
Monday, May 11, 2020
General Health, Consumer, Health, MEN, Clinical trials, Medicine, Medical specialties, Clinical medicine, RTT, Andrology, Benign prostatic hyperplasia, Men's Health, Hyperplasia, Anti-acne preparations, Benignity, Steroidal antiandrogen, Cioteronel

The "Global Benign Prostatic Hyperplasia Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Benign Prostatic Hyperplasia Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.
  • The research report Global Benign Prostatic Hyperplasia Market and Competitive Landscape - 2020, provides comprehensive insights into the Benign Prostatic Hyperplasia pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.
  • This research covers the following:
    Benign Prostatic Hyperplasia treatment options, Benign Prostatic Hyperplasia late stage clinical trials pipeline, Benign Prostatic Hyperplasia prevalence by countries, Benign Prostatic Hyperplasia market size and forecast by countries, key market events and trends, drug sales and forecast by countries, and market shares by countries.
  • Benign Prostatic Hyperplasia pipeline: Find out drugs in clinical trials for the treatment of Benign Prostatic Hyperplasia by development phase 3, phase 2, and phase 1, by pharmacological class and company
    Benign Prostatic Hyperplasia drugs: Identify key drugs marketed and prescribed for Benign Prostatic Hyperplasia in the US, including trade name, molecule name, and company
    Benign Prostatic Hyperplasia drugs sales: Find out the sales value for Benign Prostatic Hyperplasia drugs by countries
    Benign Prostatic Hyperplasia market valuations: Find out the market size for Benign Prostatic Hyperplasia drugs in 2019 by countries.

CORCEPT THERAPEUTICS PUBLISHES ABSTRACT IN THE JOURNAL OF THE ENDOCRINE SOCIETY

Retrieved on: 
Wednesday, April 1, 2020
Chemical compounds, Adrenal gland disorders, Endocrine system, Organ systems, Cushing's syndrome, Adrenocortical adenoma, Relacorilant, Hyperplasia

The abstract describes the Phase 3 trial (entitled GRADIENT) of relacorilant in patients with Cushings syndrome caused by adrenal adenomas or hyperplasia.

Key Points: 
  • The abstract describes the Phase 3 trial (entitled GRADIENT) of relacorilant in patients with Cushings syndrome caused by adrenal adenomas or hyperplasia.
  • Corcepts poster describing the trial had been accepted for presentation at the 2020 Annual Meeting of the Endocrine Society (ENDO), which has been cancelled.
  • Corcept is studying relacorilant as a potential treatment for a variety of serious disorders, including Cushings syndrome and advanced ovarian and pancreatic cancer.
  • Relacorilant is proprietary to Corcept and is protected by composition of matter and method of use patents through 2037.

Insights into the Global Benign Prostatic Hyperplasia (BPH) Treatment Devices and Equipment Global Market to 2022 - Identify Growth Segments for Investment - ResearchAndMarkets.com

Retrieved on: 
Monday, March 23, 2020
Medical devices, Health, Medicine, Clinical medicine, Medical specialties, RTT, Andrology, Benign prostatic hyperplasia, Men's Health, BPH, Benignity, Hyperplasia, Prostate steam treatment, Transurethral microwave thermotherapy

Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment Market Global Report 2020 from the author provides strategists, marketers and senior management with the critical information they need to assess the global benign prostatic hyperplasia (BPH) treatment devices and equipment market.

Key Points: 
  • Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment Market Global Report 2020 from the author provides strategists, marketers and senior management with the critical information they need to assess the global benign prostatic hyperplasia (BPH) treatment devices and equipment market.
  • The benign prostatic hyperplasia (BPH) treatment devices and equipment market consists of sales of benign prostatic hyperplasia (BPH) treatment devices and equipment and related services.
  • Global Benign Prostatic Hyperplasia Treatment Devices and Equipment Market, Split By Region, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
    5.2.
  • Global Benign Prostatic Hyperplasia Treatment Devices and Equipment Market, Split By Country, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

Millendo Therapeutics to Present at Upcoming Investor Conferences

Retrieved on: 
Thursday, March 5, 2020
Biotechnology, Pharmaceutical, Health, Endocrine system, Medicine, Medical specialties, Endocrinology, Adrenal gland disorders, Congenital adrenal hyperplasia, Menopause, Endocrine disease, Adrenal gland, Hyperplasia, Prader

A replay of the webcast will be archived on Millendos website for 30 days following the presentation.

Key Points: 
  • A replay of the webcast will be archived on Millendos website for 30 days following the presentation.
  • Millendo Therapeutics is a late-stage biopharmaceutical company primarily focused on developing novel treatments for orphan endocrine diseases where current therapies do not exist or are insufficient.
  • As a leading orphan endocrine company, Millendo seeks to create distinct and transformative treatments where there is a significant unmet medical need.
  • The company is currently advancing livoletide for the treatment of Prader-Willi syndrome, nevanimibe for the treatment of classic congenital adrenal hyperplasia and MLE-301 for the treatment of vasomotor symptoms associated with menopause.